The silicone extrusion facility Medical Elastomer Development, Inc. (“MED”), owned by Q Holding, a 3i portfolio business, has been acquired by Sanisure, a prominent, vertically-integrated participant in the single-use bioprocessing technology market. This cutting-edge plant, which is situated in Twinsburg, Ohio, provides services to numerous market leaders in the medical device and bioprocessing industries.
The acquisition increases supply security and change control (consistent E&L profiles) for our single use assembly solutions and transfer sets, and it furthers our goal of being a top supplier of crucial fluid path management technologies for bioprocessing applications. Following the acquisition, we will be able to provide end users, other OEMs, and our channel partner distributors with our fully qualified, premium bulk tubing.
Sanisure provides its customers with a broad range of capabilities on a global scale thanks to vertically integrated production and assembly facilities in both North America and Europe. Sanisure provides industry-leading options for critical fluid path technologies, such as the Mixed4Sure closed Carboy Mixing System, Cap2v8® options, PharmaTainer bottles and carboys, aSURE® fittings, Bio-Ease clamps, Gamma stable Stir Bars, as well as a wider selection of silicone extrusion and other elastomeric options like the Cellgyn® TPE, TPFE, Kynar tubing,
“We are excited to have the MED Twinsburg Team joining Sanisure’s growing family. We continue to invest in critical technologies and capabilities that drive innovation and supply security for our global customer base. State-of- the-art silicone extrusion capabilities are core to our portfolio of fluid management products and solutions, and enable us to provide both high quality silicone tubing and vertically integrated bioprocessing single-use solutions to our customers.”
Steven Chevillotte, CEO, Sanisure
“We continue to support Sanisure’s strategy through both organic and inorganic growth opportunities. This addition further strengthens Sanisure’s offering to key customers working on the development and commercialization of monoclonal antibody, vaccine, and cell and gene therapy modalities with single-use technologies in a variety of upstream and downstream applications.”
Richard Relyea, 3i Partner
